Join to View Full Profile
461 This Way StLake Jackson, TX 77566
Phone+1 979-480-9886
Fax+1 979-480-9997
Dr. Jain is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Child and Adolescent Psychiatry, 1991 - 1993- University of Texas Health Science Center at HoustonResidency, Psychiatry, 1988 - 1991
RG Kar Medical College CalcuttaClass of 1986
Certifications & Licensure
CA State Medical License 2003 - Present
TX State Medical License 1991 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2011 Jan 17
- Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex Start of enrollment: 2011 Jun 01
- This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 Start of enrollment: 2012 Jun 01
Publications & Presentations
PubMed
- Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial.Joi Dunbar, David P Walling, Howard A Hassman, Rakesh Jain, Andy Czysz
Journal of Psychopharmacology. 2024-12-01 - 10 citationsGlutamatergic Modulators for Major Depression from Theory to Clinical Use.Roger S McIntyre, Rakesh Jain
CNS Drugs. 2024-11-01 - 4 citationsTwo decades of advances in clinical oncology - lessons learned and future directions.Susana Banerjee, Christopher M Booth, Eduardo Bruera, Markus W Büchler, Alexander Drilon
Nature Reviews. Clinical Oncology. 2024-11-01
Press Mentions
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric ConditionNovember 1st, 2024- Psychedelic Therapy Could Benefit Millions of Depressed Americans, Study FindsSeptember 13th, 2024
- Congrats to the 44 Mass General Investigators Named to the Highly Cited Researchers List for 2022December 8th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
